Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medacta GroupXSWX:MOVE +1.30%91 Net Current Asset Value is CHF-0.52 as of Dec. 2025. GuruFocus rates XSWX:MOVE with a GF Score™ of 91/100 and a GF Value™ of CHF168.33 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 569 Medical Devices & Instruments companies, Medacta Group ranks worse than 175746.75% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Medacta Group's net current asset value per share for the quarter that ended in Dec. 2025 was CHF-0.52.
The historical rank and industry rank for Medacta Group's Net Current Asset Value or its related term are showing as below:
XSWX:MOVE's Price-to-Net-Current-Asset-Value is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 4.83 * Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
Medacta Group (XSWX:MOVE) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Medacta Group Net Current Asset Value Related Terms
Medacta Group Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Medacta Group's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:MOVE vs ABT, SYK, MDT: Net Current Asset Value Comparison
For the Medical Devices subindustry, Medacta Group's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medacta Group Price-to-Net-Current-Asset-Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medacta Group's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Medacta Group's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of CHF-0.52 mean?
Medacta Group (XSWX:MOVE) has a Net Current Asset Value of CHF-0.52 as of Dec. 2025. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Medacta Group and its competitors. According to the industry distribution chart, Medacta Group ranks #999999 out of 569 companies in the Medical Devices & Instruments industry.
Is Medacta Group's Net Current Asset Value too high?
Medacta Group's current Net Current Asset Value is CHF-0.52. Based on the distribution chart, Medacta Group ranks #999999 out of 569 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Medacta Group has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medacta Group's Net Current Asset Value compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medacta Group ranks #999999 out of 569 companies for Net Current Asset Value. This places Medacta Group in the lower half of its industry. The industry median Net Current Asset Value is 4.83. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Medical Devices & Instruments company?
The median Net Current Asset Value among Medical Devices & Instruments companies is 4.83, based on 569 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Medacta Group and its competitors. For the Medical Devices & Instruments industry, the median Net Current Asset Value is 4.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medacta Group's current Net Current Asset Value is CHF-0.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medacta Group stock overvalued right now?
Based on GuruFocus' analysis, Medacta Group (XSWX:MOVE) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF168.33, compared to a current price of CHF139.80 — trading 16.9% below its estimated fair value. The current Net Current Asset Value is CHF-0.52. Medacta Group's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Medacta Group (XSWX:MOVE), the current Net Current Asset Value is CHF-0.52 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medacta Group (XSWX:MOVE) Overvalued in 2026?
Based on GuruFocus' analysis, Medacta Group stock appears to be undervalued.
The current stock price of CHF139.80 is trading 16.9% below its estimated GF Value™ of CHF168.33.
GuruFocus considers Medacta Group to be Modestly Undervalued.
Key valuation signals for XSWX:MOVE:
Net Current Asset Value: CHF-0.52
GF Value™: CHF168.33 vs. price of CHF139.80 (16.9% below fair value)
No single metric tells the full story. See the XSWX:MOVE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medacta Group SA is involved in developing, manufacturing, and distributing orthopedic and neurosurgical medical devices. It specializes in the design, production, and distribution of personalized and sustainable solutions for joint replacement, sports medicine, and spine surgery. Medacta's product portfolio includes hip, knee, shoulder, and spine replacement solutions, along with a comprehensive range of sports medicine. Its products and surgical techniques are supported by an extensive program of surgeon education and engagement initiatives, enabling its offerings to be effective for the patient and surgeon. Geographically, the company derives maximum revenue from EMEA (which includes Europe, Middle East and Africa), followed by North America, Asia-Pacific, and the Latin America markets.
91GF Score
Get the complete analysis for XSWX:MOVE
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:MOVE has been successfully added to your 
